Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to document efficacy and safety data in a real-world
setting of Chinese multiple myeloma patients who have received at least one prior therapy
treated with REVLIMID (lenalidomide).